Uncategorized

Why pediatric rare oncology outperforms in a volatile biotech market

Why pediatric rare oncology outperforms in a volatile biotech market

Published

on

Real progress happens where unmet medical need is greatest and patient impact can be clearly measured. Pediatric rare cancers exemplify these criteria and have therefore generated continued investment, even in a capital-constrained environment.​ ​Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version